{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "문서 1\n",
      "ID: pubmed_16988\n",
      "paper_title: Use of the Esophageal Doppler Machine to help guide the intraoperative management of two children with pheochromocytoma.\n",
      "year: 2006.0\n",
      "\n",
      "page_content:\n",
      "Use of the Esophageal Doppler Machine to help guide the intraoperative management of two children with pheochromocytoma.\n",
      "\n",
      "The anesthetic management of pheochromocytoma has been based upon the intraoperative control of blood pressure and fluid balance following adequate preoperative preparation. This can be difficult, especially in the presence of significant comorbidity such as cardiac or renal dysfunction. Two cases of children with pheochromocytoma are reported where the introperative manageme\n",
      "--------------------------------------------------------------------------------\n",
      "문서 2\n",
      "ID: pubmed_3737\n",
      "paper_title: Hands-Only Cardiopulmonary Resuscitation Education for Elementary School Students in Korea: Tracking by School Grade, Physical Characteristics, and Physical Strength.\n",
      "year: 2023.0\n",
      "\n",
      "page_content:\n",
      "Hands-Only Cardiopulmonary Resuscitation Education for Elementary School Students in Korea: Tracking by School Grade, Physical Characteristics, and Physical Strength.\n",
      "\n",
      "Objectives: This study aimed to assess variations in chest compression depth among Korean elementary school students based on grade, physical characteristics, and strength. Methods: The study involved 140 children in the third to sixth grades from elementary schools. Before providing cardiopulmonary resuscitation (CPR) education, \n",
      "--------------------------------------------------------------------------------\n",
      "문서 3\n",
      "ID: pubmed_12460\n",
      "paper_title: Echocardiography allows for analysis of pulmonary arterial flow in mice with congenital diaphragmatic hernia.\n",
      "year: 2018.0\n",
      "\n",
      "page_content:\n",
      "Echocardiography allows for analysis of pulmonary arterial flow in mice with congenital diaphragmatic hernia.\n",
      "\n",
      "BACKGROUND: Congenital diaphragmatic hernia (CDH) is a structural birth defect associated with pulmonary hypoplasia and pulmonary arterial hypertension (PAH). We hypothesize that echocardiography provides a method to assess real-time right ventricle (RV) function, remodeling, and pulmonary artery (PA) flow.\n",
      "MATERIALS AND METHODS: Slit3 wild-type (WT) (n = 6) and knockout (KO) (n = 5) mi\n",
      "--------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "from pinecone import Pinecone\n",
    "from langchain_pinecone import PineconeVectorStore\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "\n",
    "# 환경변수 로드\n",
    "load_dotenv()\n",
    "\n",
    "# API 키 불러오기\n",
    "openai_api_key = os.environ[\"OPENAI_API_KEY\"]\n",
    "pinecone_api_key = os.environ[\"PINECONE_API_KEY\"]\n",
    "pinecone_index_name = \"boazpubmed\"  # 🔁 인덱스 이름 확인\n",
    "\n",
    "# 임베딩 모델 정의\n",
    "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\", api_key=openai_api_key)\n",
    "\n",
    "# Pinecone 연결\n",
    "pc = Pinecone(api_key=pinecone_api_key)\n",
    "index = pc.Index(pinecone_index_name)\n",
    "\n",
    "# LangChain VectorStore 생성\n",
    "vectorstore = PineconeVectorStore(\n",
    "    index=index,\n",
    "    embedding=embeddings,\n",
    "    text_key=\"page_content\"\n",
    ")\n",
    "\n",
    "# Retriever 설정\n",
    "retriever = vectorstore.as_retriever(search_kwargs={\"k\": 3})\n",
    "\n",
    "query = \"심장 초음파로 폐동맥압을 분석하는 연구는?\"\n",
    "docs = retriever.invoke(query)\n",
    "\n",
    "for i, doc in enumerate(docs, 1):\n",
    "    print(f\"문서 {i}\")\n",
    "    print(f\"ID: {getattr(doc, 'id', doc.metadata.get('source', 'N/A'))}\")\n",
    "    print(f\"paper_title: {doc.metadata.get('paper_title', '제목 없음')}\")\n",
    "    print(f\"year: {doc.metadata.get('year', '연도 없음')}\")\n",
    "    print(\"\\npage_content:\")\n",
    "    print(doc.page_content[:500])\n",
    "    print(\"-\" * 80)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'neo4j_retriever': StructuredTool(name='neo4j_retriever', args_schema={'properties': {'query': {'title': 'Query', 'type': 'string'}}, 'required': ['query'], 'title': 'neo4j_retrieverArguments', 'type': 'object'}, response_format='content_and_artifact', coroutine=<function convert_mcp_tool_to_langchain_tool.<locals>.call_tool at 0x7211476c2560>), 'VectorDB_retriever': StructuredTool(name='VectorDB_retriever', args_schema={'properties': {'query': {'title': 'Query', 'type': 'string'}}, 'required': ['query'], 'title': 'VectorDB_retrieverArguments', 'type': 'object'}, response_format='content_and_artifact', coroutine=<function convert_mcp_tool_to_langchain_tool.<locals>.call_tool at 0x7211476c2b00>)}\n"
     ]
    }
   ],
   "source": [
    "from typing import Annotated, List, TypedDict\n",
    "from langgraph.graph.message import add_messages\n",
    "from langchain_community.document_transformers import LongContextReorder\n",
    "from langgraph.checkpoint.memory import MemorySaver\n",
    "from langchain_core.messages import AIMessage\n",
    "from langgraph.graph import StateGraph, START, END\n",
    "from dotenv import load_dotenv\n",
    "from langchain_openai import ChatOpenAI\n",
    "from mcp import ClientSession, StdioServerParameters\n",
    "from langchain_mcp_adapters.client import MultiServerMCPClient\n",
    "from openai import OpenAI\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "model_client = OpenAI()\n",
    "\n",
    "class ChatbotState(TypedDict):\n",
    "    question: Annotated[str, \"Question\"]  \n",
    "    tools: Annotated[List, \"Tools\"]\n",
    "    neo4j_documents: Annotated[List, \"Neo4j_Documents\"]  \n",
    "    vector_documents : Annotated[List,\"Vector_Documents\"]\n",
    "    final_answer: Annotated[str, \"Final_Answer\"]  \n",
    "    messages: Annotated[List, add_messages] \n",
    "\n",
    "memory = MemorySaver()\n",
    "\n",
    "# MCP Multi-Tool Client\n",
    "client = MultiServerMCPClient(\n",
    "    {\n",
    "        \"neo4j_retriever\": {\n",
    "            \"command\": \"/home/hyewon/boaz/bin/python\",\n",
    "            \"args\": [\"/mnt/c/Users/user/BOAZ_ADV/Hyewon/mcp/mcp_neo4j_server.py\"],\n",
    "            \"transport\": \"stdio\",\n",
    "        },\n",
    "        \"VectorDB_retriever\": {\n",
    "            \"command\": \"/home/hyewon/boaz/bin/python\",\n",
    "            \"args\": [\"/mnt/c/Users/user/BOAZ_ADV/Hyewon/mcp/mcp_vectordb_server.py\"],\n",
    "            \"transport\": \"stdio\",\n",
    "        },\n",
    "    }\n",
    ")\n",
    "\n",
    "tools = await client.get_tools()\n",
    "\n",
    "tools_dict = {tool.name: tool for tool in tools}\n",
    "\n",
    "print(tools_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "tools = [\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"name\": \"neo4j_retriever\",\n",
    "        \"description\": \"Query structured patient-related data, such as surgeries, lab results, or graph-based records.\",\n",
    "        \"parameters\": {\n",
    "            \"type\": \"object\",\n",
    "            \"properties\": {\n",
    "                \"query\": {\n",
    "                    \"type\": \"string\",\n",
    "                    \"description\": \"Query about the patient's clinical records\"\n",
    "                }\n",
    "            },\n",
    "            \"required\": [\"query\"],\n",
    "            \"additionalProperties\": False\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"name\": \"VectorDB_retriever\",\n",
    "        \"description\": \"Retrieve general medical knowledge (diseases, treatments, guidelines).\",\n",
    "        \"parameters\": {\n",
    "            \"type\": \"object\",\n",
    "            \"properties\": {\n",
    "                \"query\": {\n",
    "                    \"type\": \"string\",\n",
    "                    \"description\": \"Query about medical knowledge\"\n",
    "                }\n",
    "            },\n",
    "            \"required\": [\"query\"],\n",
    "            \"additionalProperties\": False\n",
    "        }\n",
    "    }\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "LLM_SYSTEM_PROMPTY = \"\"\"\n",
    "# INSTRUCTION\n",
    "당신은 의료 데이터에 특화된 전문가 AI입니다.\n",
    "사용자의 질문에 대해 다음 두 가지 출처의 정보를 참고하여 답변을 생성하세요:\n",
    "\n",
    "1. 🔎 Neo4j 검색 결과: 구조화된 환자 관련 정보 (예: 수술 이력, 검사 기록 등)\n",
    "2. 📚 VectorDB 검색 결과: 일반적인 의학 지식 (예: 증상 설명, 치료 가이드라인 등)\n",
    "\n",
    "- 두 결과 모두 존재할 경우, 각 출처를 구분하여 통합적으로 반영하되, 중복 내용은 요약하거나 통합하세요.\n",
    "- 한 쪽의 결과만 존재할 경우, 해당 결과만을 바탕으로 답변하되, 정보의 한계에 대해 언급하지 말고 최대한 성실히 답변하세요.\n",
    "- 결과가 너무 적거나 애매하더라도 반드시 유의미한 설명을 제공하려고 노력하세요.\n",
    "- 불필요한 서론 없이, 질문에 바로 답변하세요.\n",
    "\n",
    "# Neo4j CONTEXT\n",
    "{Neo4j}\n",
    "\n",
    "# Vector DB CONTEXT\n",
    "{VectorDB}\n",
    "\n",
    "# Question\n",
    "{question}\n",
    "\"\"\"\n",
    "\n",
    "model = ChatOpenAI(temperature=0.2,\n",
    "                      model_name=\"gpt-4o\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "async def decision_tools(state: ChatbotState):\n",
    "    \n",
    "    question = state[\"question\"]\n",
    "\n",
    "    input_messages = [\n",
    "        {\"role\": \"system\", \"content\": \"Decide which tools to use to answer the user's question. You may call one or both.\"},\n",
    "        {\"role\": \"user\", \"content\": question}\n",
    "    ]\n",
    "    \n",
    "    response = model_client.responses.create(model=\"gpt-4.1\",\n",
    "                                             input=input_messages,\n",
    "                                             tools=tools)\n",
    "\n",
    "    selected_tools = [tool.name for tool in response.output]\n",
    "\n",
    "    return ChatbotState(tools=selected_tools)\n",
    "\n",
    "async def vector_db(state: ChatbotState):\n",
    "    question = state[\"question\"]\n",
    "    \n",
    "    if \"VectorDB_retriever\" in state[\"tools\"]:\n",
    "        vectordb_tool = tools_dict[\"VectorDB_retriever\"]\n",
    "        \n",
    "        if vectordb_tool:\n",
    "            result = await vectordb_tool.ainvoke({\"query\": question})\n",
    "        else:\n",
    "            result = \"VectorDB 도구를 찾을 수 없습니다.\"\n",
    "    else:\n",
    "        result = None\n",
    "\n",
    "    return ChatbotState(vector_documents=result)\n",
    "\n",
    "async def neo4j_db(state: ChatbotState):\n",
    "    question = state[\"question\"]\n",
    "    \n",
    "    if \"neo4j_retriever\" in state[\"tools\"]:\n",
    "        neo4j_tool = tools_dict.get(\"neo4j_retriever\")\n",
    "        if neo4j_tool:\n",
    "            result = await neo4j_tool.ainvoke({\"query\": question})\n",
    "        else:\n",
    "            result = \"Neo4j 도구를 찾을 수 없습니다.\"\n",
    "    else:\n",
    "        result = None\n",
    "\n",
    "    return ChatbotState(neo4j_documents=result)\n",
    "\n",
    "async def merge_outputs(state:ChatbotState):\n",
    "\n",
    "    question = state['question']\n",
    "    vector_documents = state['vector_documents']\n",
    "    neo4j_documents = state['neo4j_documents']\n",
    "\n",
    "    formatted = LLM_SYSTEM_PROMPTY.format(Neo4j = neo4j_documents,\n",
    "                                          VectorDB = vector_documents,\n",
    "                                          question = question)\n",
    "    response = model.invoke(formatted)\n",
    "    response_text = response.content if isinstance(response, AIMessage) else str(response)\n",
    "\n",
    "    return ChatbotState(final_answer=response_text,\n",
    "                        messages=[(\"user\", question), (\"assistant\", response_text)])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<langgraph.graph.state.CompiledStateGraph object at 0x721139b08100>"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "builder = StateGraph(ChatbotState)\n",
    "\n",
    "builder.add_node(\"decision_tools\", decision_tools)\n",
    "builder.add_node(\"vector_db\", vector_db)\n",
    "builder.add_node(\"neo4j_db\", neo4j_db)\n",
    "builder.add_node(\"merge_outputs\", merge_outputs)\n",
    "\n",
    "builder.add_edge(START, \"decision_tools\")\n",
    "\n",
    "def route_tools(state: ChatbotState):\n",
    "    return state[\"tools\"]\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"decision_tools\",\n",
    "    route_tools,\n",
    "    {\n",
    "        \"neo4j_retriever\": \"neo4j_db\",\n",
    "        \"VectorDB_retriever\": \"vector_db\"\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_edge(\"neo4j_db\", \"merge_outputs\")\n",
    "builder.add_edge(\"vector_db\", \"merge_outputs\")\n",
    "builder.add_edge(\"merge_outputs\", END)\n",
    "\n",
    "builder.compile(checkpointer=memory)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'decision_tools': {'tools': ['VectorDB_retriever']}}\n",
      "{'vector_db': {'vector_documents': 'Laparoscopic cholecystectomy for symptomatic cholecystolithiasis (CCL) in \"Kasabach-Merritt syndrome\" (KMS) (Kaposi-tumor like hemangioendothelioma with case-specific perioperative management).\\n\\nOBJECTIVES: The Kasabach-Merritt syndrome (KMS) is characterized by the occurrence of hemangioendothelioma (giant hemangioma with thrombosis leading to thrombocytopenia), which can be associated with disseminated intravasal coagulation. Specific aim: Based on (i) selective references from the current scientific literature and derived recommendations as well as (ii) own experiences obtained in the diagnostic and perioperative management of a representative case from daily practice in abdominal surgery, the specific case undergoing elective cholecystectomy (CCE) in KMS is to be described by means of scientific case report.\\nCASE PRESENTATION: (Patient-, finding- and treatment-specific characteristics): - Medical history: 72-years old female patient with a known KMS of the left arm and upper thorax, recurrent thrombophlebitis of the left arm and thoracic veins, previous upper GI bleeding (Mallory-Weiss syndrome in 2006, chronic anemia in lack of vitamin B12, type-A gastritis, former bleeding complications after teeth extraction/open appendectomy 1962/Caesarean section 1968 with need of transfusion [60 red blood cell packages]), intraabdominal adhesions, hypothyreosis, initial liver cirrhosis. - Symptomatology: Characteristic for cholecystolithiasis (CCL). - Diagnostic: Abdominal ultrasound shows CCL, fibroscan does not confirm suspicious cirrhosis. Laboratory parameters showed: Activation of intravasal coagulation with elevated prothrombin fragments, D-dimers and reduced antiplasmin concentration. Accelerated fibrinolysis capacity; currently, no secondary thrombocytopenia or factor-13 decrease. In addition, fibrinogen concentration within normal range, no hint onto the manifestation of an aquired von-Willebrand\\'s syndrome. - Diagnosis: Chronic fibrosing cholecystitis in CCL after former acute cholecystitis (3\\u202fmonths ago) with indication for surgical intervention. - Therapy: Laparoscopic CCE including careful exploration of upper abdominal cavity for KMS manifestation (with no revision of bile duct) and peritoneal adhesiolysis (histological finding, chronic fibrosing cholecystitis with thickening of the wall of the gall bladder but no hint of malignancy) under perioperative prophylaxis with antibiotics and temporary cessation of platelet medication for 7\\u202fd preoperatively, \"bridging\" with low molecular weight heparin (Clexane, 1 × 40\\u202fmg\\u202fs.c.; Sanofi-Aventis, Frankfurt/Main, Germany); 1\\u202fh preoperatively, 15-20\\u202fmg/kg body weight Cyclocapron i.v. (once again 6-8\\u202fh postoperatively; thereafter, 500\\u202fmg of Cyclocapron 4×/d until the 3rd postoperative day). - Intraoperatively: Congestion of veins but not at the immediate surgical field (gall bladder, hepatic bed of the gall bladder, Calot\\'s triangle). - Outcome: Uneventful, in particular, no (bleeding) complications.\\nCONCLUSIONS: If surgical approach is indicated, the intervention should be thoroughly planned (in particular, under elective circumstances) with regard to hemangioma site and extension as well as distance to the surgical field and possible surgical alternative options (surgical access site, open/laparoscopic approach etc.) to prevent - at the best possible rate - bleeding complications intra-/postoperatively and, thus, to provide adequate patient safety.\\nEfficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach-Merritt phenomenon in infants, a retrospective study.\\n\\nOBJECTIVE: This retrospective study aimed to observe the efficacy of transcatheter arterial chemoembolization (TACE) combined with sirolimus in the treatment of haemangioma combined with the Kasabach-Merritt phenomenon (KMP).\\nMETHODS: A total of 11 infants with KMP who were treated at our hospital from January 2016 to September 2021 were selected and treated with arteriosclerosis embolotherapy using a microsphere emulsion formed by bleomycin\\u2009+\\u2009ultra-fluid lipiodol\\u2009+\\u2009dexamethasone\\u2009+\\u2009contrast agent or bleomycin mixed microspheres as the embolising agent. The patients were administered sirolimus orally after TACE. The clinical efficacy and examination indicators before and after treatment were observed and compared.\\nRESULTS: The 11 infants underwent TACE treatment by arteriosclerosis embolotherapy a total of 21 times; of these cases, 10 were cured, and 1 showed a moderate response. There were no cases of non-response or death. The platelet count rose from 10.0 (7.0, 18.0) x 109/L before TACE to 236.0 (188.0, 275.0) x 109/L six months after the first TACE, and the tumour size decreased from 49.0 (43.0, 111.7) cm3 before TACE to 7.0 (3.5, 17.0) cm3 six months after the first TACE. The differences were statistically significant (the Z values were -2.943 and -2.934, respectively, p\\u2009&lt;\\u20090.05).\\nCONCLUSION: The combination of TACE and sirolimus has significant efficacy on critical children with KMP.\\nSingle Large-Scale Mitochondrial DNA Deletion Syndromes\\n\\nCLINICAL CHARACTERISTICS: Single large-scale mitochondrial DNA deletion syndromes (SLSMDSs) comprise overlapping clinical phenotypes including Kearns-Sayre syndrome (KSS), KSS spectrum, Pearson syndrome (PS), chronic progressive external ophthalmoplegia (CPEO), and CPEO-plus. KSS is a progressive multisystem disorder with onset before age 20 years characterized by pigmentary retinopathy, CPEO, and cardiac conduction abnormality. Additional features can include cerebellar ataxia, tremor, intellectual disability or cognitive decline, dementia, sensorineural hearing loss, oropharyngeal and esophageal dysfunction, exercise intolerance, muscle weakness, and endocrinopathies. Brain imaging typically shows bilateral lesions in the globus pallidus and white matter. KSS spectrum includes individuals with KSS in addition to individuals with ptosis and/or ophthalmoparesis and at least one of the following: retinopathy, ataxia, cardiac conduction defects, hearing loss, growth deficiency, cognitive impairment, tremor, or cardiomyopathy. Compared to CPEO-plus, individuals with KSS spectrum have more severe muscle involvement (e.g., weakness, atrophy) and overall have a worse prognosis. PS is characterized by pancytopenia (typically transfusion-dependent sideroblastic anemia with variable cell line involvement), exocrine pancreatic dysfunction, poor weight gain, and lactic acidosis. PS manifestations also include renal tubular acidosis, short stature, and elevated liver enzymes. PS may be fatal in infancy due to neutropenia-related infection or refractory metabolic acidosis. CPEO is characterized by ptosis, ophthalmoplegia, oropharyngeal weakness, variable proximal limb weakness, and/or exercise intolerance. CPEO-plus includes CPEO with additional multisystemic involvement including neuropathy, diabetes mellitus, migraines, hypothyroidism, neuropsychiatric manifestations, and optic neuropathy. Rarely, an SLSMDS can manifest as Leigh syndrome, which is characterized as developmental delays, neurodevelopmental regression, lactic acidosis, and bilateral symmetric basal ganglia, brain stem, and/or midbrain lesions on MRI.\\nDIAGNOSIS/TESTING: The diagnosis of an SLSMDS is established in a proband with characteristic clinical features by identification of a mitochondrial DNA (mtDNA) deletion ranging in size from 1.1 to 10 kb on molecular genetic testing. SLSMDSs can be identified in DNA from blood, buccal cells, and urine in affected children; analysis of skeletal muscle tissue may be required to detect an SLSMDS in an affected adult.\\nMANAGEMENT: Targeted therapy: Folinic acid supplementation in individuals with KSS with low 5-methyltetrahydrofolate in CSF or white matter abnormalities on brain MRI. Supportive care: Consider mitochondrial supplement therapies such as coenzyme Q<sub>10</sub> and antioxidants; optimize nutrition and exercise regimen to prevent acute decompensation; physical and occupational therapy for myopathy and/or ataxia; standard treatment with anti-seizure medication; hearing aids or cochlear implants for sensorineural hearing loss; developmental and educational support; feeding therapy; consider gastrostomy tube placement if poor weight gain, choking, or aspiration risk is present; dilation of the upper esophageal sphincter to alleviate cricopharyngeal achalasia; prophylactic placement of cardiac pacemaker in individuals with cardiac conduction block, with consideration of an implantable cardioverter defibrillator; hormone replacement therapy per endocrinologist; electrolyte monitoring and replacement for renal tubular acidosis; eyelid slings and/or ptosis repair for severe ptosis; eye ointment for dry eyes; eyeglass prisms for diplopia; transfusion therapy for individuals with PS with sideroblastic anemia; replacement of pancreatic enzymes for exocrine pancreatic insufficiency; ventilatory support for respiratory abnormalities that may occur in individuals with Leigh syndrome; standard treatment of anxiety and/or depression; social work support and care coordination as needed. Surveillance: Annual neurology assessment for ataxia, neuropathy, seizures, and myopathy; annual audiology evaluation; annual assessment of developmental progress, educational needs, and cognitive issues; annual evaluation by a neuro-ophthalmologist and/or retinal specialist and oculoplastics; measurement of growth parameters and evaluation of nutritional status and safety of oral intake at each visit; annual assessment of mobility and self-help skills with physical medicine, occupational therapy, and/or physical therapy; EKG and echocardiogram every six to 12 months; annual assessment with an endocrinologist; BUN and creatinine, with consideration of cystatin C in those with low muscle mass; complete blood count in those with PS to assess transfusion needs with additional labs per hematologist, and ferritin for those needing recurrent transfusions as needed; annual complete blood count in those with other SLSMDSs; fecal fat and fecal elastase as needed based on symptoms; monitor for evidence of aspiration and respiratory insufficiency at each visit; assess family needs at each visit. Agents/circumstances to avoid: Volatile anesthetic hypersensitivity may occur. Avoid prolonged treatment with propofol (&gt;30-60 minutes). Medications should be reviewed with a physician familiar with mitochondrial disorders including a thorough individualized assessment of risk vs benefit as several medications may be toxic to mitochondria.\\nGENETIC COUNSELING: SLSMDSs are almost never inherited, suggesting that these disorders are typically caused by a de novo single large-scale mitochondrial DNA deletion (SLSMD) that occurs in the mother\\'s oocytes during germline development or in the embryo during embryogenesis. If the mother is clinically unaffected and the proband represents a simplex case (i.e., a single affected family member), the empiric risk to the sibs of a proband is very low (at or below 1%). If the mother is affected, the recurrence risk to sibs is estimated to be approximately 4% (one in 24 births). Maternal transmission to more than one child has not been reported to date. Prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are scientifically possible but technically prohibitive as next-generation sequencing methodology does not accurately quantify heteroplasmy level of an SLSMD and droplet digital quantitative PCR cannot reliably detect less than 10% heteroplasmy levels of an SLSMD. Further, prenatal testing is not clinically available due to the inability to accurately interpret the clinical prognosis based on prenatal diagnostic results of an SLSMD.\\nClinical feature and genetic mutation of KBG syndrome diagnosed in neonatal period: A case report.\\n\\nRATIONALE: KBG syndrome (KBGS, OMIM: 148050), a rare genetic disorder, is clinically characterized by megalodontia, short stature, skeletal abnormalities, and nervous system manifestations. In the study, we explore the clinical and genetic characteristics of one neonate suffering KBGS caused by ANKRD11 gene mutation.\\nPATIENT CONCERNS: The proband, a female, was born prematurely at 31\\u2009+\\u20092 weeks. There were repeated infections and abdominal distension in the first month after birth, and the platelets could not rise to normal. Head ultrasound showed intracranial brain injury and intracranial hemorrhage.\\nDIAGNOSES: Sequencing revealed that there was a heterozygous mutation in exon 9 of the ANKRD11 gene (NM_013275.5) for the child, c.1896_1897delTA (p.H632Qfs*30), which was a de novo mutation and has not been reported. Combining clinical features and genetic results, the proband was diagnosed as KBGS.\\nINTERVENTIONS AND OUTCOMES: The brain sonography on day 4 after birth showed brain injury and intracranial hemorrhage. Therefore, 140\\u2009mg of bovine lung surfactant was administered through endotracheal intubation in addition to ventilator-assisted ventilation. Antibiotic treatment was also given till the inflammatory indicators of the infant returned to normal levels. The following-up of 1-year-6-month showed that the language, motion and height of development is slight falling behind the children of the same age.\\nLESSONS: This is the first case of KBGS was diagnosed in the neonatal period, which provides a reference for the child to receive timely and correct treatment.\\nMulticenter registry of multisystem inflammatory syndrome in children (MIS-C) and Paired comparison with Kawasaki disease.\\n\\nOBJECTIVES: This study aimed to identify clinical characteristics to differentiate multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease (KD) in Taiwan, an island with a delayed cluster of MIS-C and a high incidence of KD. Additionally, we studied risk factors for developing severe complications in patients with MIS-C.\\nMETHODS: We conducted a retrospective, multicenter, cohort, and observational study that linked data on patients with MIS-C between May and December 2022 and patients with KD between 2019 and 2021 from 12 medical centers. Hemodynamic compromise, defined as the need for inotropic support or fluid challenge, was recorded in patients with MIS-C. We also evaluated maximal coronary Z-scores before treatment and one month after disease onset.\\nRESULTS: A total of 83 patients with MIS-C and 466 patients with KD were recruited. A 1:1 age and gender-matched comparison of 68 MIS-C and KD pairs showed that MIS-C patients had a lower percentage of positive BCG red halos, lower leukocyte/platelet counts, more gastrointestinal symptoms, and a higher risk of hemodynamic compromise. In Taiwan, 38.6% of MIS-C patients experienced hemodynamic compromise, with presence of conjunctivitis and elevated levels of procalcitonin (>1.62\\xa0ng/mL) identified as independent risk factors.\\nCONCLUSIONS: We identified two independent risk factors associated with hemodynamic compromise in MIS-C patients. The comparison between matched MIS-C and KD patients highlighted significant differences in clinical presentations, like BCG red halos, which may aid in the differential diagnosis of the two disease entities, especially in regions with a high incidence rate of KD.'}}\n",
      "{'merge_outputs': {'final_answer': 'Kasabach-Merritt Syndrome (KMS)는 혈관종과 관련된 드문 혈액학적 질환으로, 주로 hemangioendothelioma라는 거대 혈관종이 발생하여 혈소판 감소증을 유발하는 것이 특징입니다. 이로 인해 혈액 내 혈소판 수치가 감소하고, 혈관 내 응고 장애가 발생할 수 있습니다. KMS는 종종 전신성 혈관 내 응고 장애와 연관될 수 있으며, 이는 출혈 위험을 증가시킵니다.\\n\\n치료 방법으로는 혈관종의 크기를 줄이기 위한 다양한 접근법이 사용됩니다. 예를 들어, 영아에서 Kasabach-Merritt 현상을 치료하기 위해 경동맥 화학색전술(TACE)과 시롤리무스를 병용하는 방법이 효과적이라는 연구 결과가 있습니다. 이 치료는 혈소판 수치를 증가시키고 종양 크기를 감소시키는 데 유의미한 효과를 보였습니다.\\n\\nKMS 환자가 수술을 필요로 할 경우, 수술 계획은 혈관종의 위치와 확장을 고려하여 신중하게 이루어져야 하며, 출혈 합병증을 최소화하기 위한 예방 조치가 필요합니다.', 'messages': [('user', 'Kasabach-Merrritt Syndrome이 뭐야?'), ('assistant', 'Kasabach-Merritt Syndrome (KMS)는 혈관종과 관련된 드문 혈액학적 질환으로, 주로 hemangioendothelioma라는 거대 혈관종이 발생하여 혈소판 감소증을 유발하는 것이 특징입니다. 이로 인해 혈액 내 혈소판 수치가 감소하고, 혈관 내 응고 장애가 발생할 수 있습니다. KMS는 종종 전신성 혈관 내 응고 장애와 연관될 수 있으며, 이는 출혈 위험을 증가시킵니다.\\n\\n치료 방법으로는 혈관종의 크기를 줄이기 위한 다양한 접근법이 사용됩니다. 예를 들어, 영아에서 Kasabach-Merritt 현상을 치료하기 위해 경동맥 화학색전술(TACE)과 시롤리무스를 병용하는 방법이 효과적이라는 연구 결과가 있습니다. 이 치료는 혈소판 수치를 증가시키고 종양 크기를 감소시키는 데 유의미한 효과를 보였습니다.\\n\\nKMS 환자가 수술을 필요로 할 경우, 수술 계획은 혈관종의 위치와 확장을 고려하여 신중하게 이루어져야 하며, 출혈 합병증을 최소화하기 위한 예방 조치가 필요합니다.')]}}\n"
     ]
    }
   ],
   "source": [
    "from langchain_core.runnables import RunnableConfig\n",
    "\n",
    "config = RunnableConfig(configurable={\"thread_id\": 1})\n",
    "\n",
    "question = \"Kasabach-Merrritt Syndrome이 뭐야?\"\n",
    "\n",
    "graph = builder.compile(checkpointer=memory)\n",
    "\n",
    "initial_state = {\n",
    "    \"question\": question,\n",
    "    \"tools\": [],\n",
    "    \"neo4j_documents\": [],\n",
    "    \"vector_documents\": [],\n",
    "    \"final_answer\": \"\",\n",
    "    \"messages\": [],\n",
    "}\n",
    "\n",
    "events = []\n",
    "async for event in graph.astream(initial_state, config=config):\n",
    "    print(event)\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (boaz)",
   "language": "python",
   "name": "boaz"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
